29 adult patients admitted to the ICU due to COVID‐19. The patients were treated with the IL‐6R inhibitor tocilizumab (8 mg/kg to a maximum of 800 mg) in a single dose 24 h after ICU admission. Models were developed to evaluate if bodyweight would be a factor for dosage. Here, IL6R is linked to COVID-19.